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Immunostimulatory properties of mushroom derived polysaccharides (PS) as stand-alone agents were
tested. Next, PS were nanocomplexed with polyI:C (pIC) to yield stable nanoparticles around 200 nm in
size evidenced by atomic force microscopy and dynamic light scattering analyses. PSs were selectively
engaged by cells expressing TLR2 and initiated NFkB dependent signaling cascade leading to a Th1-
biased cytokine/chemokine secretion in addition to bactericidal nitric oxide (NO) production from
macrophages. Moreover, cells treated with nanoparticles led to synergistic IL6, production and upre-
gulation of TNFa, MIP3a, IFNg and IP10 transcript expression. In mice, PS-Ovalbumin-pIC formulation
surpassed anti-OVA IgG responses when compared to either PS-OVA or pIC-OVA mediated immunity.
Our results revealed that signal transduction initiated both by TLR2 and TLR3 via co-delivery of pIC by PS
in nanoparticle depot delivery system is an effective immunization strategy. The present work implicate
that the PS and nucleic acid based nanoparticle approach along with protein antigens can be harnessed
to prevent infectious diseases.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
Toll-like receptors (TLRs) are the most extensively studied
pathogen recognition receptors (PRRs) that recognizes speciﬁc
microbial associated molecular patterns (MAMPs) including lipo-
polysaccharides, peptidoglycans, lipoproteins, ﬂagellin, unmethy-
lated CpG motifs or viral RNA/DNA that triggers innate immune
response [1e3]. TLRs are subcategorized as endosomal or intracel-
lular receptors dependingon their site of expression. TLR3, 7/8 and 9
are specialized to sense pathogens via their nucleic acids moieties
[4]. TLR3, a member of endosome-associated TLR is activated
directly in response to dsRNA, or synthetic poly(riboinosinic:polyr-
ibocytidylic acid) (pIC) [5] and are harnessed as vaccine adjuvant,
anti-cancer or anti-allergic therapeutic agents. When these ligands
are given in vivo, they are rapidly cleared by nucleases, and could be
adsorbed by serum proteins hampering their in vivo therapeuticMDC, Bone marrow derived
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All rights reserved.applications [6]. In order to improve their immune stimulatory
potential repeated high doses are necessary, however, in many
instances this may cause undesirable side effects including septic
shock [7]. Nucleic acid backbone modiﬁcations such as phosphor-
othioate linkages are another widely accepted approach but this not
only induces undesirable side effects such as granuloma formation,
temporary splenomegaly, and lymphadenopathy but also increases
the cost of the ﬁnal product [8e11].
Several strategies were proposed as carriers for labile nucleic
acids attempting to increase their in vivo performances [12e14].
Among many, liposome encapsulation, biodegradable nano/micro
carriers and soluble macromolecules with cationic moieties were
widely studied [12e14]. We and others demonstrated that, uptake,
duration and in vivo immunostimulatory activity of oligodeox-
ynucleotides enhanced when encapsulated in sterically stabilized
cationic liposomes (SSCL) [15e17]. Although co-administration of
pIC with liposomes induced anti-viral immunity and activated
effective CD8þ T cells in vivo [18], still several obstacles prevent
these depot delivery systems enter into clinic. Of note, batch to
batch variation, limited shelf-life, difﬁculty in reproducible recon-
stitution and sterility are the major concerns from FDA stand point.
Furthermore, organic solvents used during the production of
certain formulations are of major concern [19e21].
In the present study, natural amphiphilic polysaccharides puriﬁed
from mushrooms were studied to assess their immunostimulatory
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Fig. 1. Dose dependent TNFa, and NO, induction from RAW cells following 24 h post-
stimulation with different b-Glucan polymers. A) TNFa and B) NO were detected by
ELISA and Griess assay, respectively from cell supernatants. Result represents combi-
nation of at least two independent experiments (mean  SEM) of triplicate samples
treated with different stimulants (0.02e20 mg/ml). PS4 vs PS2 comparison gave
a p < 0.001 for TNFa (at all doses) and p < 0.004 for NO (at 0.02 mg/ml).
G. Tincer et al. / Biomaterials 32 (2011) 4275e42824276potential. Later, a nanoparticle delivery system was formulated to
efﬁciently harbour pIC. The TLR2 mediated PS targeting and subse-
quent initiation of signal transduction cascade and ability of the
nanoparticles to inducesynergistic immuneactivationwasevaluated.
Furthermore, inan immunizationstudy inmiceco-deliveringamodel
protein antigen ovalbumin (OVA), immunogenicity of PS-OVA-pIC
nanoparticles was compared to either PS-OVA or pIC-OVA mediated
immune response.
2. Materials and methods
2.1. Materials
All cell culturemedia components were fromHyclone (USA). Cytokine, IgG ELISA
were from Endogen and Southern Biotech, respectively (USA). TLR ligands were
obtained from several vendors: peptidoglycan (PGN) (Fluka, Switzerland), pIC
(Amersham, UK). b-Glucan based polysaccharides were provided by Prof. Oktay
Erbatur (Cukurova University, Chem Dept., Adana, Turkey). A high pressure/high
temperature stainless steel reactor (Parr 4575 HT/HP) with 500 ml volumewas used
for extraction of polysaccharide at subcritical water conditions from different
mushrooms. The sugar content of the extracts was determined by HPLC (Varian
Prostar210, equipped with a RI detector) against monosaccharide standards and
protein determination by Lowry assay. Monosaccharide analyses of the PS yielded
mainly glucose, in addition to mannose and galactose. The purity was found to be
>93%. Following protease digestion to eliminate protein contamination purity
reached over 97%. Molecular weight determination was carried out by high
performance size exclusion chromatography (on a HPSEC-MALLS system). In this
study, polysaccharides were abbreviated as PS1 to PS4. Their physicochemical
characteristics were as follow: i) Ganoderma lucidum (Alata strain)-PS1 (Ave. MWt:
2.9  106 Da and pKa: 6.64), ii) G. lucidum (Balcalı strain)-PS2 (Ave. MWt:
3.8  106 Da and pKa: 6.99), iii) Shiitake-PS3 (Ave. MWt:1.6  106 Da and pKa: 6.67),
and iv) G. lucidum (Alata strain)-PS4 (Ave. MWt: 5.2  106 Da and pKa: 6.69).
Endotoxin levels for all PSs were checked by LAL assay and were found to be
undetectable (minimum detection limit of the assay was 0.01 EU/ml). PS nano-
complexes with pIC (1:1 w/w, PS:ligand ratio) were prepared overnight at 4 C.
Unbound pIC was ﬁltered (Microspin G-25 column) free nucleic acid concentration
was measured by Nanodrop from the eluent. pIC incorporationwas over 90% in all
preliminary trials.
2.2. Mice
Adult C57BL/6 and BALB/C mice (female, 6e8 weeks old) were housed in
Department of Molecular Biology and Genetics, facility and were provided with
unlimited access of food and water. All experimental procedures were approved by
the animal ethical committee of Bilkent University (Bil-AEC/Protocol#: 2006/027).
RAW 264.7 cells (ATCC) or splenocytes were culturedwith RPMI 1640 supplemented
with 5% FBS, 50 mg/ml penicillin/streptomycin, 2 mM L-glutamine, 10 mM HEPES
buffer, 0,11 mg/ml sodium pyruvate. HEK 293 or stably hTLR2 transfected cells
(Invivogen, USA), were kept in high-glucose DMEM media with 10% FBS,
2.3. Immunization
Adult female C57/BL6 mice (5/group) were injected ip with of PS, pIC (15 mg
each) or PS-pIC nanocomplex combined with 7.5 mg of OVA. One day before booster
injection (@d ¼ 13) animals were bled and next day injected with the same
formulations. On day 28 mice were bled. Sera from the primary and secondary
bleedings were studied for total IgG, IgG1, and IgG2a by ELISA.
2.4. ELISA and NO assays
Immulon 2 HB microtitre plates (Thermo Scientiﬁc, USA) were coated with anti-
cytokine or anti-IgG antibodies and then blocked with PBS-BSA 1% [17,35]. Serially
diluted standards and culture supernatants or mouse sera were added to these
plates for 2 h. Cytokine was detected using biotinylated anti-cytokine Ab (TNFa:
XT22 and IL6: 2OF3 clones) followed by phosphatase-streptavidin (Perbio Pierce,
USA) whereas bound IgG subclasses were detected using phosphatase-conjugated
anti-IgG, IgG1, and IgG2a antibodies as described elsewhere [17]. Nitric oxide
detection by Griessmethodwas conducted on RAW264.7 cells (105/ml) after 6e48 h
of incubation as described by the suppliers (Promega WI, USA).
2.5. Luciferase assay
hTLR2 expressing HEK cells were transfected using FuGENE6 with p5xlucNFkB
luciferase as described inmanufacturer’s protocol. Following overnight stimulations,
cells were further incubated for 24e36 h and were harvested and assayed for
luciferase activity (Roche, Germany). Plots were generated from relative light units.2.6. Cytokine and chemokine RT-PCR
Total RNA was extracted from the cells that were treated either with PS or with
pIC nanocomplexes for 2e6 h. They were reverse-transcribed and ampliﬁed to
obtain cDNA in a standard PCR reaction for 30 cycles using primers for murine
speciﬁc target genes (Supplementary Table S2) as previously described [35,36]. PCR
ampliﬁed material was separated on 2% agarose gels and visualized under UV light
after ethidium bromide staining.
2.7. Atomic force microscopy (AFM) and size measurement studies of the
nanocomplexes
pIC, PS4 and their nanocomplexes were diluted in DNase/RNase free H2O and
were deposited on silicon wafer. Following complete drying images were taken by
using non-contact mode XE-100E model AFM (PSIA with XEI 1.6 software incorpo-
rated) with a 0.73e0.79 Hz scanning rate. The scanning area sizes were in 1  1 mm.
Particle size analyses of the generated nanocomplexes were measured using dynamic
light scattering method on a zetasizer (Model: Nano ZS, Malvern, UK).
2.8. Statistical analysis
Statistical signiﬁcant differences between groups were determined using
Student’s t- test analysis via SigmaSTAT software. P values < 0.05 were considered
signiﬁcant.
3. Results
3.1. TNFa and nitric oxide production by polysaccharides
Initial experiments were designed to understand the immu-
nostimulatory potential of the four PS candidates in dose-titration
(20e0.02 mg/ml) assays. A well established positive control pepti-
doglycan (PGN) was run in parallel to compare the response raised
by b-Glucan polymers. Fig. 1 shows that when RAW cells were
treated with different PSs for 24 h, a dose dependent TNFa (Fig. 1A)
and NO (Fig. 1B) production were induced especially by PS2 and
PS4. PS4 was the most active among other tested PSs at doses
AG. Tincer et al. / Biomaterials 32 (2011) 4275e4282 4277greater or equal to 0.2 mg/ml (Fig. 1A). In the case of NO induction
PS4 was superior (at all doses) than the rest of the stimulants
including positive control PGN (Fig. 1B).
3.2. PS mediated upregulation of various cytokine/chemokine
transcripts
To examine the kinetics of PS driven immune activation RAW cells
were incubatedwith different b-Glucan stimulants. The culture ﬂuids
collected at different time intervals (6, 12, 24, 36, and 48 h after
stimulation) after 2 mg/ml PS treatments were assayed for TNFa
(Fig. 2A) and bactericidal mediator NO (Fig. 2B). As seen in Fig. 2A, as
early as 6 h post-stimulation all PS types secreted substantial amount
of TNFa. Among the testedgroups, only PS4 typecontinued to increase
TNFa level by 48 h. Similarly, nitric oxide secretionproﬁles of different
PStypesgavea time-dependent response.Again, consistentwithFig.1,
only PS2 and PS4 (Fig. 2B) displayed time-dependent NO production
frommacrophages. Also these b-Glucans’ effects on mRNA transcript
upregulation of TLRs as well as various cytokines were assessed after
4 h incubation. When TLR transcript levels of an untreated mouse
splenocyteswere compared to thatof PS treated cells’ transcript levels
PS2 and PS4 treatment highly upregulated expression of tlr1, 2, 5, 7,
and 9 genes (Supplementary Figure S1A). Moreover, compared to
untreatedvs PS treated cells,mRNAband intensities for il-15, il-18,and
TNFa signiﬁcantly increasedonlyuponPS4 treatment (Supplementary
Figure S1B). These results suggested that PS4 and then PS2 poly-
saccharides were the most potent stimulants.
3.3. Engagement of PS by TLR2
Several b-Glucan polymers were reported to trigger signaling
cascade either using cell surface expressed TLR2 (alone or engagingA
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Fig. 2. Time dependent TNFa, and NO release by RAW cells following different PS
treatments at 2 mg/ml. A) TNFa and B) NO levels were assessed by ELISA and Griess
assay respectively. Result represents combination of at least three independent
experiments (mean  SEM) of triplicate samples treated at different time points (6 h,
12 h, 24 h, 36 h & 48 h). PS4 vs PS1, PS2 (except 12 h) or PS3 comparison gave
a p < 0.01 for TNFa (at all time points) and for NO, PS4 vs PS2 is NS, and PS4 vs PS1 or
PS3 is p < 0.001 (at all time points except 6 h).TLR1 or TLR6), TLR4 or even cytosolic sensors such as NOD1 and
NOD2 [22,31]. To differentiate between these alternatives HEK cells
stably expressing hTLR2, hTLR4 or TLR2/6 genes were transfected
with p5xlucNFkB and in subsequent experiments co-transfected
with pcDNA3NOD1 or pcDNA3NOD2 or mock plasmids to check
whether these PS polymers either engages only through TLRs or
additionally interact with the cytosolic NOD sensors. In Fig. 3,
NFkB-mediated luciferase activity studies demonstrated that PS
triggers via TLR2 receptor (Fig. 3A) and furthermore regulates IL8
production (Fig. 3B). Expression of TLR6 did not improve TLR2
mediated promoter activation (data not shown). Consistent with
previous results, PS4 is the most potent inducer. Of note, other TLRs
or NODs were not contributing to this immune cascade since
subsequent experiments demonstrated that there was no further
signiﬁcant increase (either luciferase activity or IL8 production)
mediated by PS treatment of cells expressing TLR4, or NOD1 or
NOD2 (data not shown).
3.4. PS4 activity upon in vivo administration to mice
These four PSs were given to mice (2 mg/ml) and 6 h later PEC
and spleen cells were recovered and incubated in culture without
further stimulation to evaluate cytokine production or chemokine
message transcript upregulation by ELISA and RT-PCR, respectively.
Consistent with previous observations, PS4 was the most active
stimulant among the tested polysaccharides. It yielded the highest
IL6 production fromPECs after 48 h ex-vivo incubation (Fig. 4A). The
spleen cells TNFa and IP10 transcript levels were signiﬁcantly
upregulated when PS1, 2, and 3 vs PS4 band intensities were0
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Fig. 3. PS mediated promoter assay and IL8 production by hTLR2-HEK cells. A) Relative
luciferase activity after PS treatment of stable hTLR2-HEK cells. Cells were transfected
with p5xlucNFkB plasmid for 24 h and stimulated with 5 mg/ml of each PS for 12 h. B)
IL8 production following PS treatment. Stable hTLR2-HEK cells were stimulated with
5 mg/ml of each PS for 24 h. IL8 ELISA was studied from the culture supernatants. Data
represents combination of at least two independent experiments (mean  SEM) of
triplicate samples treated with different stimulants (PS1-4, PGN and LPS). PS4 vs PS1, 2,
3 and LPS gave a p < 0.001.
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Fig. 4. In vivo immunostimulatory activity of polysaccharides. A) Six hours after i.p. PS
injection (2 mg/ml), PECs were isolated (3 mice/group). Cells (4  106/ml) were incu-
bated ex-vivo for further 24 h or 48 h, IL6 levels from supernatants were measured by
cytokine ELISA. Fold induction of IL6 production over naive cells was plotted (naive
cells induced 56  13 @ 24 h and 164  23 @ 48 h pg/ml IL6). B) mRNA levels of TNFa
and IP10 were assessed by RT-PCR from spleen cells. Densitometric measurements
(obtained from 3 independent mice) for the gel band intensities were plotted. PS4 vs
PS1, 2 and 3 gave a p < 0.001.
G. Tincer et al. / Biomaterials 32 (2011) 4275e42824278compared, (Fig. 4B). Although previously PS2 activity in culture was
similar to PS4, surprisingly it failed to reproduce this trend when
administered in vivo. When in vitro and in vivo data are collectively
considered, among four tested PS candidates, PS4 consistently
displayed the highest immunostimulatory performance, and was
selected to develop PS4-pIC nanoparticles.
3.5. Physical characterization of PS4-pIC nanocomplexes
When nucleic acids are injected in vivo they are either subjected
to premature digestion by nucleases or adsorbed by serum proteins,
therefore, hampering their bioavailability. Accumulating evidence
strongly suggested that their in vivo applications are limited due to
their labile nature. Strategies to improve their stability as well as
retaining activity and facilitate their cellular internalization
without premature clearance are of great importance to pursue
these ligands into clinical use [15,17]. To establish whether PS4-pIC
complexes form stable nanoparticles their physical characteristics
by i) AFM and by ii) dynamic light scattering techniques (Zetasizer
Nano, ZS) were studied. AFMphotomicrographs revealed that PS4
appeared as individual nanoparticles around 50e70 nm in size
(Fig. 5). This was further conﬁrmed by Zetasizer and was found to
be ca. 40  20 nm (Ave  SEM) (Supplementary Figure S2). PS4
nanocomplex with pIC led to an increase in the nanoparticle size
from 40 nm to 165 nm (Supplementary Figure S2). The stability of
these nanocomplexes was also studied by dynamic light scattering
method using Zetasizer. There was no signiﬁcant change in the size
of the generated nanocomplexes over a period of two weeks indi-
cating that there was no spontaneous fusion (or disintegration) of
the individual particles when suspended either in PBS or in FBSsupplemented media (Supplementary Table S1, and data not
shown).
3.6. Synergistic immune activation by PS4-pIC nanoparticles
Next we analyzed the immunostimulatory effect of PS4 nano-
complexes harbouring one of the labile nucleic acid ligands, pIC.
Whether it improves pIC dependent immune activation to that of its
free form is of great interest. As presented in Fig. 6, PS4-pIC nano-
particles induced synergistic activation on both RAW264.7 ormouse
spleen cells upon in vitro or in vivo treatments. PS4epIC nano-
complexes led to a signiﬁcantly high IL6 production (Fig. 6 and data
not shown). It is important to note that pIC alone, when given at this
concentration could not produce any detectable IL6, however, the
nanoparticlesyielded125057ng/mlof IL6 secretion. Thisamount is
>6x fold more cytokine production to that of PS4 alone stimulation
(Fig. 6A left panel). Furthermore, macrophages stimulated by these
nanocomplexes induced very strong bactericidal mediator, NO
compared to either of the PS4 alone or pIC alone treatments
(Supplementary Figure S3). When spleen cells were incubated with
PS4-pIC nanocomplexes, the gene message levels of tnfa, il15, il18,
mip3a, and ip10 were signiﬁcantly upregulated (compared to either
PS4 alone or pIC alone treatments, Fig. 6B). The activity of these
nanocomplexes were further analyzed following ip injection of mice
(3/group) and checking IFNg transcript level from recovered spleen
cells (Fig. 6C). Consistently, PS4-pIC nanocomplex treated animals
displayed thehighest ifngmessage. These results stronglysupport the
synergistic activation mediated by the nanocomplex.
3.7. Immunization with PS4-pIC nanoparticles
To examine whether the PS4-pIC nanoparticles could act as an
effective immune adjuvant/delivery system, ovalbumin (OVA) was
loaded as the model antigen and C57BL/6 mice were immunized.
Primary and secondary bleeding sera were analyzed to detect the
levels of total IgG, IgG1 and IgG2a. As seen in Fig. 7, total IgG and
anti-OVA speciﬁc IgG subtypes were signiﬁcantly boosted by the
PS4-OVA-pIC nanoparticles when compared to dual combination
groups (i.e. pIC þ OVA or PS þ OVA). This was evident even after
primary immunization, since therewas 2e3-foldmore anti-OVA Ab
induction at 1/2000 antibody titre, (Fig. 7A). As expected, signiﬁ-
cantly higher magnitude of total IgG, IgG1 as well as IgG2a titers
were obtained after booster injection. In Fig. 7B, at titre 1/8000, all
IgG types were improved at least 2- fold and up when mice were
immunized with the nanocomplex. These data implied that
generated stable nanoparticles ensured simultaneous internaliza-
tion of the adjuvant (signal 1) and antigen (signal 2) by antigen
presenting cells (APCs), thereby led to stronger anti-OVA immunity.
4. Discussion
Natural polysaccharides extracted from mushrooms was shown
to activate host immune system leading to production of various
Th1-biased cytokines [23]. One approach to induce an improved
immune response is to ensure that these formulations achieve
simultaneous presentation of antigen and adjuvant to relevant
APCs. Developing such systems that act in synergy with the loaded
adjuvant may further improve the success of the therapy and help
host defence [14,24e26].
In this study, PS/Nucleic acid ligand nanocomplexes were
designed to solve several key problems associated with poor in vivo
performance. Polysaccharides used in this study are; i) naturally
occurring, readily available, easily extracted in bulk ii) cheap iii)
does not require sophisticated formulation technology as it is water
soluble iv) readily undergoes stable interaction with charged
Fig. 5. AFM photomicrographs of phase, 2D phase (left) and 3D topography (middle and right) images. A) PS4, B) pIC and C) PS4-pIC nanoparticles at 1000 nm2 area. Images were
recorded under contact mode.
G. Tincer et al. / Biomaterials 32 (2011) 4275e4282 4279macromolecules due to their amphiphilic nature v) effectively
engage by cells expressing TLR2 on their surface (i.e. natural tar-
geting), vi) the labile cargo is protected from premature degrada-
tion/elimination and ﬁnally vii) act as a co-adjuvant in vaccine
formulations along with the adjuvant to augment Ag-dependent
immune activation. Our ﬁndings strongly suggest that all these key
features are fulﬁlled by the developed formulation.
Recent studies showed that a natural b-glucan polysaccharide
isolated from Schizophyllan modiﬁed with peptides and cholesterol
formed a complex with TLR9 ligand, CpG ODNs and signiﬁcantly
elevated secretion of cytokines (IL12, IL6 and TNFa) from BMDCs,
and murine macrophages [27,28]. These compounds were proposed
to trigger several immune cells through various receptors including
complement receptor (CR3), scavenger receptors, as well as TLR4 or
TLR2/6 [29e32]. In other study,G. lucidum polysaccharides enhanced
CD14 mediated endocytosis of LPS and promoted TLR2/4 signal
transduction of cytokine expression [31].
Contrary to previous reports, our ﬁndings suggested that mush-
room derived PS polymers recognized only via TLR2 but not via TLR4
or TLR2/6. Furthermore, to date, there is no document reporting the
collaborative activation of TLR3 ligand with PS obtained from edible
mushrooms.Moreover, in thepresent studyplainPS compoundswere
used with no further modiﬁcation (i.e cholesterol or peptide). The
cytokine secretion panels (dose-dependent and time-dependent
ﬁndings) presented in Figs. 1 and 2 clearly suggested that PS4 is the
most potent stimulant. Moreover, in HEK cell system we establishedthat these PS types only interact with TLR2 (Fig. 3) but not with other
cell surface or cytosolic receptors (NOD1 or 2). In the literature,
receptor usage of PS is still elusive. This is probably due to the problem
associated with the extraction of PS from different sources. Similar
compounds were reported to trigger a group of immune cells
including macrophages, neutrophils, monocytes, natural killer cells
and dendritic cells through various receptors including Dectin-1 and
scavenger receptors [31,32]. We have attempted to delineate the
contribution of PS mediated activation via the scavenger receptor
CXCL16. It was found that it does not involve in PS mediated cytokine
production, since there was no up or down regulation of the cxcl16
gene transcript (Supplementary Figure S2).However, Dectin-1hasnot
been studied here, and must be checked to resolve its involvement.
We further assessed the nitric oxide production mediated by
different PS compounds. Since NO is an important regulator and
mediator of macrophage directed cytotoxicity against microbes and
tumour cells, detecting the most potent NO inducer as well as estab-
lishing thebreadthof activationpatternof PS4wasverycritical [33,34].
The results of in vitroﬁndingswere reproduced in vivo (Figs.1, 2 and4).
Among all tested PSs, consistently PS4 triggered the highest IL6
production in addition toNO secretion aswell as enhanced several key
cytokine/chemokine gene expression in PECs and splenocytes. This is
the ﬁrst example to demonstrate that a polysaccharide extracted from
mushrooms induced strong NO production from immune cells.
PS4-pIC nanoparticles supported the added effect of formulating
them as a carrier depot system. In addition to IL6 production by
Fig. 6. PS-pIC nanoparticles induced higher IL6 production and strong gene upregulation of various cytokine and chemokines after in vitro and in vivo stimulations. A) RAW cell
supernatants from 36 h culture were analyzed by ELISA. Result represents combination of at least two independent experiments (mean  SEM) of triplicate samples. p < 0.002
nanocomplexes vs nucleic acid alone treated groups. B) After stimulation with PS4 (0.016 mg/ml) or PS4-pI:C (0.16 mg/ml each) for 4 h in culture, total RNA from spleen cells were
subjected to RT-PCR and cDNA were ampliﬁed against gene-speciﬁc primers. C) PS4-pIC nanoparticles (2 mg each) was injected to mice and spleen cells were recovered 18 h post-
treatment for IFNg transcript analyses (inlet; representative band intensities from a single animal). Band intensities were reported as average of 3 mice/group.
G. Tincer et al. / Biomaterials 32 (2011) 4275e42824280
Fig. 7. IgG anti-OVA response of immunized mice. Animals were injected i.p with 15 mg of PS4 þ pIC combination or PS4-pIC nanoparticles incorporating 10 mg OVA. Serum anti-
OVA titers at day 13 (A) and day 28 (B) were determined by Total IgG, IgG1 and IgG2a ELISA. Data represents the average  SD serum IgG anti-OVA response (ﬁve mice per group).
G. Tincer et al. / Biomaterials 32 (2011) 4275e4282 4281immune cells compared to their alone treatments (Fig. 6A), data
also demonstrated that several cardinal chemokine and cytokine
mRNA messages were upregulated (Fig. 6B). The in vivo beneﬁt of
PS4-pIC nanocomplexes were documented in ex vivo study along
with model antigen immunization study. Data suggested that these
formulations could improve primary and booster immunity against
OVA antigen (Fig. 7). This is primarily due to the fact that, the
present formulation helped avoiding premature clearance and
digestion of its cargo as well as increased stability and efﬁcient
delivery of OVA þ adjuvant simultaneously to APCs, thereby
resulting more pronounced immune response.
5. Conclusions
The present work established that combination of mushroom
derived polysaccharide and pIC forms stable nanocomplexes and
triggered upregulation of inﬂammatory cytokines, and bactericidal
mediators as evidenced by dose and time-dependent kinetic
proﬁles of, IL6, IL18, TNFa and NO productions. Immune enhance-
ment of PS is dependent on TLR2 signaling, compounded by the pIC
mediated TLR3 signaling resulted stronger pro-inﬂammatory effect
of the formulation. When used in vivo as a protein vaccine carrier,
nanocomplex led to elevated IgG titers against ovalbumin antigen
in mice, compared to either PSþ OVA or pICþOVA immunizations.
In conclusion, present system can be formulated with other clini-
cally valuable bioactive agents such as siRNA, plasmids, and
different nucleic acid based TLR ligands, along with peptides or
proteins as vaccine carriers to control infectious pathogenic insults.
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